53 completed, 24 recruiting, 12 terminated, 12 unknown. 33 Phase 4, 27 Phase 2, 27 Phase 3, 11 Phase 1, 4 Not applicable.
Follow vedolizumab: new trials by email Literature Review of vedolizumab trials Research Report on vedolizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination CurQD and Vedolizumab in Ulcerative Colitis CurQD, Placebo, Vedolizumab - Ulcerative Colitis | Phase 4 | Not yet recruiting | Ryan C Ungaro | 160 | 2026-10-01 | 2026-10-05 |
| Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer Vedolizumab, Placebo - IrAE, Immune-related Adverse Event | Phase 2 / Phase 3 | Recruiting | AHS Cancer Control Alberta | 36 | 2026-08-13 | 2026-08-27 |
| PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure methoxsalen, Extracorporeal photopheresis (ECP), Vedolizumab - Colitis, Hepatitis | Phase 2 | Not yet recruiting | Therakos LLC | 112 | 2026-07-01 | 2026-06-02 |
| Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population Non-Interventional Study - Ulcerative Colitis | Active not recruiting | Pfizer | 4000 | 2026-04-01 | 2026-10-15 | |
| Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt adalimumab, infliximab, ustekinumab, golimumab, and vedolizumab - Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis) | Not yet recruiting | Assiut University | 95 | 2026-03-01 | 2026-03-27 | |
| Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease Infliximab, Adalimumab, Vedolizumab - Inflamatory Bowel Disease, Crohn Disease (CD) | Recruiting | Shanghai 10th People's Hospital | 198 | 2026-01-16 | 2026-07-10 | |
| EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis Methoxsalen, Infliximab, Vedolizumab - Immune-related Colitis | Phase 2 | Withdrawn | Therakos LLC | 2025-12-15 | 2025-12-26 | |
| A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) Vedolizumab SC, No Intervention - Ulcerative Colitis, Crohn's Disease | Phase 3 | Recruiting | Takeda | 70 | 2025-10-27 | 2026-10-09 |
| Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial Vedolizumab 300 MG Injection [Entyvio], Prednisone (and methylprednisolone), Prednisone Taper - Immune Checkpoint Inhibitor-Related Colitis | Phase 2 | Recruiting | Shilpa Grover, MD, MPH | 80 | 2025-07-15 | 2025-11-04 |
| A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab Risankizumab, Vedolizumab - Ulcerative Colitis | Phase 3 | Active not recruiting | AbbVie | 573 | 2025-06-17 | 2026-08-04 |
| Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis OD-07656, Vedolizumab - Ulcerative Colitis (UC), UC - Ulcerative Colitis | Phase 2 | Recruiting | Odyssey Therapeutics, Inc. | 57 | 2025-06-02 | 2026-02-11 |
| Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2025-04-18 | 2026-06-29 |
| A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting Vedolizumab IV, Vedolizumab SC - Ulcerative Colitis, Crohn's Disease | Phase 4 | Recruiting | Takeda | 200 | 2025-03-27 | 2026-10-20 |
| A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Vedolizumab IV, Vedolizumab SC - Ulcerative Colitis, Crohn's Disease | Phase 3 | Recruiting | Takeda | 70 | 2025-01-22 | 2026-08-03 |
| A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease Vedolizumab, Upadacitinib, Placebo - Crohn's Disease | Phase 3 | Recruiting | Takeda | 396 | 2025-01-02 | 2026-05-27 |
| Vedolizumab for the Treatment of Collagenous Gastritis Vedolizumab - Collagenous Gastritis | Phase 2 | Active not recruiting | Massachusetts General Hospital | 11 | 2024-12-03 | 2026-06-16 |
| A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis Vedolizumab, Concomitant Antibiotic Therapy - Pouchitis | Phase 3 | Recruiting | Takeda | 30 | 2024-11-19 | 2026-08-03 |
| Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. Adalimumab, Vedolizumab - Crohn's Disease | Phase 4 | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 220 | 2024-10-31 | 2026-05-05 |
| Vedolizumab in Pediatric Ulcerative Colitis- Comparison With Infliximab Infliximab - Ulcerative Colitis | Phase 3 | Not yet recruiting | JAROSLAW KIERKUS | 60 | 2024-10-01 | 2024-09-26 |
| Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio AVT16, Vedolizumab - Ulcerative Colitis | Phase 3 | Terminated | Alvotech Swiss AG | 301 | 2024-09-23 | 2025-12-26 |
Showing 20 of 123. Sign in to see all of them.
Colitis, Ulcerative (61) · Crohn Disease (49) · Inflammatory Bowel Diseases (13) · Colitis (7) · Graft vs Host Disease (4) · Melanoma (4) · Carcinoma, Non-Small-Cell Lung (3) · Myelodysplastic Syndromes (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, Biphenotypic, Acute (2) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Pouchitis (2) · Urogenital Neoplasms (2) · Acquired Immunodeficiency Syndrome (1)
Takeda (36) · Millennium Pharmaceuticals, Inc. (10) · Alimentiv Inc. (3) · Second Affiliated Hospital of Wenzhou Medical University (3) · Sixth Affiliated Hospital, Sun Yat-sen University (3) · ANRS, Emerging Infectious Diseases (2) · Ced Service GmbH (2) · Centre Hospitalier Universitaire de Saint Etienne (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2) · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa (2) · Geert D'Haens (2) · M.D. Anderson Cancer Center (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Therakos LLC (2) · Universitaire Ziekenhuizen KU Leuven (2)
United States (57) · Canada (30) · Belgium (22) · United Kingdom (22) · Italy (21) · Poland (20) · France (18) · Spain (17) · China (16) · Hungary (16) · Israel (16) · Netherlands (15) · Germany (14) · South Korea (14) · Japan (13)
Vipul Jairath, MD (2) · Yinghong Wang (2) · Yves Levy, MD (2) · Aaron Etra, MD (1) · Aida Habtezion, MD (1) · Amar R Deshpande, MD (1) · Andres J Yarur, MD (1) · Benjamin Misselwitz, Prof. (1)
PMID 26893500, PMID 25996351, PMID 32635680, PMID 29857145, PMID 30203005, PMID 35934286, PMID 23964932, PMID 27802155, PMID 30365009, PMID 30615117, PMID 33200296, PMID 12219789, PMID 12556782, PMID 12809831, PMID 17960014, PMID 18829392, PMID 21131921, PMID 22619366, PMID 22751454, PMID 22825365, PMID 23163616, PMID 23468464, PMID 23964933, PMID 24763133, PMID 24859203, PMID 25271602, PMID 25434285, PMID 26641955, PMID 27639327, PMID 29295985, PMID 29471381, PMID 29533533, PMID 29730603, PMID 29788318, PMID 29869016, PMID 30285104, PMID 30807613, PMID 31173898, PMID 31279871, PMID 31470005, PMID 31553834, PMID 31633731, PMID 31821456, PMID 32062041, PMID 32606883, PMID 32806876, PMID 32876349, PMID 33033101, PMID 33210333, PMID 33454706
2023 (9), 2015 (5), 2014 (4), 2016 (4), 2018 (4), 2008 (3), 2017 (3), 2019 (2), 2009 (1), P30CA033572 (1)